Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I6IQ
|
|||
| Drug Name |
Neihulizumab
|
|||
| Indication | Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 2 | [1] | |
| Company |
AbGenomics International Los Altos, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin glycoprotein ligand 1 (SELPLG) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.